Get started
Author

Bassam Bassam Sonbol

Observed names: B B Sonbol, B Sonbol, Bassam Sonbol
OpenAlex ID: A5033844346
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
2023 · Samuel J Klempner, Bassam Bassam Sonbol, et al. · Journal of Clinical Oncology · 14
PDF
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
2022 · Samuel J Klempner, Joseph Chao, et al. · Journal of Clinical Oncology · 12
Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.
2024 · Cody Eslinger, Alyssa McGary, et al. · Journal of Clinical Oncology · 4
PDF
Development of an improved risk stratification scheme for stage II and III colorectal cancers through incorporation of the digital pathology biomarker QuantCRC.
2024 · Rish Pai, Christina Wu, et al. · Journal of Clinical Oncology · 3
Efficacy of pembrolizumab as first-line therapy in patients with mismatch repair–deficient metastatic colorectal cancer in relation to the metastatic site.
2023 · Bahar Saberzadeh Ardestani, Jeremy Clifton Jones, et al. · Journal of Clinical Oncology · 3
PDF
Responses to immune checkpoint inhibition among MSI-H pancreatic ductal adenocarcinoma: A multi-institutional case series.
2022 · Tucker Coston, Jason S. Starr, et al. · Journal of Clinical Oncology · 3
The impact of peptide receptor radionucleotide therapy with Lutetium-177 DOTATATE on cardiac metastases in neuroendocrine tumors
2024 · I Scalia, B Sonbol, et al. · European Heart Journal · 1
PDF
Clinical outcomes and molecular characteristics of patients with pancreatic acinar cell carcinoma.
2024 · Cody Eslinger, Claire Yee, et al. · Journal of Clinical Oncology · 1
Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment.
2024 · Osama M Mosalem, Tucker Coston, et al. · Journal of Clinical Oncology · 1
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
2024 · Bahar Saberzadeh Ardestani, Jeremy Clifton Jones, et al. · Journal of Clinical Oncology · 1
PDF
Source of funding and enrollment disparities in the inclusion of minorities in colorectal clinical trials: A systematic review and meta-analysis.
2023 · Ahsan Ayaz, Syed Arsalan Ahmed Naqvi, et al. · Journal of Clinical Oncology · 1
P17.34.b Belzutifan in Clinical Practice: Outcomes and Safety in a Real-world Cohort of Patients With Vhl-associated Neoplasms
2025 · M H Ser, T M Galloway, et al. · Neuro-Oncology
PDF
From neuroendocrine neoplasms to sarcomas: how genetic testing reveals diagnostic pitfalls
2025 · Oudai Sahvan, Bassam Sonbol, et al. · Endocrine Abstracts
Utilizing quantitative pathologic analysis of digitized images of rectal cancer (RC) to predict response to neoadjuvant therapy (NAT).
2024 · Daniel Walden, Cody Eslinger, et al. · Journal of Clinical Oncology
PDF
Social vulnerability and gastrointestinal cancer mortality among United States counties.
2023 · Syed Arsalan Ahmed Naqvi, Yusra Saleem, et al. · Journal of Clinical Oncology
Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma.
2022 · Patrick Walsh McGarrah, Jennifer Gile, et al. · Journal of Clinical Oncology
REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.
2022 · Daniel H. Ahn, Fang-Shu Ou, et al. · Journal of Clinical Oncology
Works count: 17
Citation count: 44
H-index: 3
I10-index: 2
Year
Topic
Type